Skip to main content
Top
Published in: Journal of Gastrointestinal Cancer 3/2010

01-09-2010 | Brief Communication

Regression of Immunoproliferative Small Intestinal Disease After Eradication of Helicobacter pylori

Authors: Usha Dutta, Harsh Udawat, Mohd Talha Noor, Gurbakhshish Singh Sidhu, Rakesh Kochhar, Kim Vaiphei, Kartar Singh

Published in: Journal of Gastrointestinal Cancer | Issue 3/2010

Login to get access

Abstract

A 20-year-old male presented with low-grade fever, abdominal pain, anorexia, and weight loss of 4-month duration. On examination, he was emaciated. Barium meal follow-through examination showed extensive nodularity and thickening of duodenal and jejunal folds. Contrast-enhanced computed tomography of the abdomen revealed extensive proximal small-bowel thickening with mesenteric lymphadenopathy. Upper gastrointestinal endoscopy and enteroscopy revealed thickening of folds with multiple small superficial ulceration involving antrum, duodenum, and jejunum. The duodenal and jejunal biopsy was suggestive of immunoproliferative small intestinal disease, stage 0 (Salem) or stage A (Galian). Antral biopsy showed presence of Helicobacter pylori infection. He underwent H. pylori eradication following which he had significant clinical improvement; repeat evaluation at 6 months showed dramatic improvement in his clinical, radiological, and histological parameters.
Literature
1.
go back to reference Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low grade B-cell gastric lymphoma of mucosa associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993;342:575–7.CrossRefPubMed Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low grade B-cell gastric lymphoma of mucosa associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993;342:575–7.CrossRefPubMed
2.
go back to reference Martin IG, Aldoori MI. Immunoproliferative small intestinal disease: Mediterranean lymphoma and α heavy chain disease. Br J Surg. 1994;81:20–4.CrossRefPubMed Martin IG, Aldoori MI. Immunoproliferative small intestinal disease: Mediterranean lymphoma and α heavy chain disease. Br J Surg. 1994;81:20–4.CrossRefPubMed
3.
go back to reference Bull D. Alpha-chain disease and related small intestinal lymphoma: a memorandum. Bull World Health Organ. 1976;54:615–24. Bull D. Alpha-chain disease and related small intestinal lymphoma: a memorandum. Bull World Health Organ. 1976;54:615–24.
4.
go back to reference Rambaud JC, Halphen M, Galian A, Tsapis A. Immunoproliferative small intestinal disease (IPSID): relationships with alpha-chain disease and “Mediterranean” lymphomas. Springer Semin Immunopathol. 1990;12:239–50.CrossRefPubMed Rambaud JC, Halphen M, Galian A, Tsapis A. Immunoproliferative small intestinal disease (IPSID): relationships with alpha-chain disease and “Mediterranean” lymphomas. Springer Semin Immunopathol. 1990;12:239–50.CrossRefPubMed
5.
go back to reference Khojasteh A, Haghighi P. Immunoproliferative small intestinal disease: portrait of a potentially preventable cancer from the Third World. Am J Med. 1990;89:483–90.CrossRefPubMed Khojasteh A, Haghighi P. Immunoproliferative small intestinal disease: portrait of a potentially preventable cancer from the Third World. Am J Med. 1990;89:483–90.CrossRefPubMed
6.
go back to reference Khojasten A. Immunopathology of the small intestine. In: Marsh MN, editor. Chichester. United Kingdom: Wiley; 1987. p. 121–50. Khojasten A. Immunopathology of the small intestine. In: Marsh MN, editor. Chichester. United Kingdom: Wiley; 1987. p. 121–50.
7.
go back to reference Fine KD, Stone MJ. Alpha-heavy chain disease, Mediterranean lymphoma, and immunoproliferative small intestinal disease: a review of clinicopathological features, pathogenesis, and differential diagnosis. Am J Gastroenterol. 1999;94:1139–52.PubMed Fine KD, Stone MJ. Alpha-heavy chain disease, Mediterranean lymphoma, and immunoproliferative small intestinal disease: a review of clinicopathological features, pathogenesis, and differential diagnosis. Am J Gastroenterol. 1999;94:1139–52.PubMed
8.
go back to reference Jaffe ES, Harris NL, Stein H, Vardiman JW. Tumors of hematopoietic and lymphoid tissue. Lyon: IARC; 2001. Jaffe ES, Harris NL, Stein H, Vardiman JW. Tumors of hematopoietic and lymphoid tissue. Lyon: IARC; 2001.
9.
go back to reference Al-Saleem T, Al-Mondhiry H. Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms. Blood. 2005;105:2274–80.CrossRefPubMed Al-Saleem T, Al-Mondhiry H. Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms. Blood. 2005;105:2274–80.CrossRefPubMed
10.
go back to reference Santhi Swaroop V, Advani SH, Damle SR, et al. Spectrum of alpha chain disease in India. Indian J Cancer. 1983;20:261–7. Santhi Swaroop V, Advani SH, Damle SR, et al. Spectrum of alpha chain disease in India. Indian J Cancer. 1983;20:261–7.
11.
go back to reference Akbulut H, Soykan I, Yakaryilmaz F, et al. Five year results of the treatment of 23 patients with immunoproliferative small intestinal disease: a Turkish experience. Cancer. 1997;80:8–14.CrossRefPubMed Akbulut H, Soykan I, Yakaryilmaz F, et al. Five year results of the treatment of 23 patients with immunoproliferative small intestinal disease: a Turkish experience. Cancer. 1997;80:8–14.CrossRefPubMed
12.
go back to reference Nikbin B, Banisadre M, Ala F, Kijtabai A. HLA AW 19, B12 in immunoproliferative small intestinal disease. Gut. 1979;20:226–8.CrossRefPubMed Nikbin B, Banisadre M, Ala F, Kijtabai A. HLA AW 19, B12 in immunoproliferative small intestinal disease. Gut. 1979;20:226–8.CrossRefPubMed
13.
go back to reference Crabbé PA, Nash DR, Bazin H, Eyssen H, Heremans JF. Immunohistochemical observations on lymphoid tissues from conventional and germ free mice. Lab Invest. 1970;22:448–57.PubMed Crabbé PA, Nash DR, Bazin H, Eyssen H, Heremans JF. Immunohistochemical observations on lymphoid tissues from conventional and germ free mice. Lab Invest. 1970;22:448–57.PubMed
14.
go back to reference Bayerdorffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet. 1995;345:1591–4.CrossRefPubMed Bayerdorffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet. 1995;345:1591–4.CrossRefPubMed
15.
go back to reference Alkan S, Karcher DS, Newman MA, Cohen P. Regression of salivary gland MALT lymphoma after treatment Helicobacter pylori. Lancet. 1996;348:268–9.CrossRefPubMed Alkan S, Karcher DS, Newman MA, Cohen P. Regression of salivary gland MALT lymphoma after treatment Helicobacter pylori. Lancet. 1996;348:268–9.CrossRefPubMed
16.
go back to reference Fischback W, Tacke W, Greiner HK, Hermelink M. Regression of immunoproliferative small intestinal disease after eradication of Helicobacter pylori. Lancet. 1997;349:31–2.CrossRef Fischback W, Tacke W, Greiner HK, Hermelink M. Regression of immunoproliferative small intestinal disease after eradication of Helicobacter pylori. Lancet. 1997;349:31–2.CrossRef
17.
go back to reference Rambaud JC. Small intestinal lymphomas and alpha-chain disease. Clin Gastroenterol. 1983;12:743–6.PubMed Rambaud JC. Small intestinal lymphomas and alpha-chain disease. Clin Gastroenterol. 1983;12:743–6.PubMed
Metadata
Title
Regression of Immunoproliferative Small Intestinal Disease After Eradication of Helicobacter pylori
Authors
Usha Dutta
Harsh Udawat
Mohd Talha Noor
Gurbakhshish Singh Sidhu
Rakesh Kochhar
Kim Vaiphei
Kartar Singh
Publication date
01-09-2010
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 3/2010
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-010-9138-z

Other articles of this Issue 3/2010

Journal of Gastrointestinal Cancer 3/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine